QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Thalidomide and Congenital Malformations

Test your understanding of the concepts covered by Thalidomide and Congenital Malformations: A Historical Signal Evaluation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why are modern thalidomide controls designed primarily to prevent fetal exposure rather than merely describe the risk in product information?

The risk is serious, established and potentially preventable through controlled use and pregnancy-prevention measures The drug has no therapeutic benefits in any patient population Warnings are never appropriate for medicines used by women of childbearing potential Pregnancy exposure cannot be detected through clinical follow-up

Question 2 of 10 Which conclusion would be most scientifically appropriate after an early cluster of limb-reduction defects among thalidomide-exposed pregnancies?

The absolute risk is known and can be stated precisely The cluster is sufficient to generate a serious causal hypothesis requiring further evaluation All other possible causes have been excluded The drug should be considered harmless until a molecular mechanism is identified

Question 3 of 10 Which statement best distinguishes signal validation from risk quantification?

A signal must have a precise absolute risk before any regulatory review is justified A signal can be credible enough to warrant action even while the exact absolute risk remains uncertain Risk quantification is unnecessary once a signal has been reported Signal validation concerns only molecular mechanism, whereas risk quantification concerns only clinical phenotype

Question 4 of 10 Which causal consideration most distinguishes the thalidomide signal from a nonspecific report of any birth defect after drug exposure?

The exposure occurred at some point before delivery The outcome was severe, characteristic and compatible with exposure during a developmental window The mother had taken the medicine for at least one day The event was reported by a healthcare professional

Question 5 of 10 Why did independent observations by McBride and Lenz materially strengthen the thalidomide signal?

They constituted two independent randomised controlled trials They reduced the likelihood that the finding was solely a local coincidence or observer-specific bias They proved that the risk was identical in all countries and populations They eliminated the need to examine exposure timing

Question 6 of 10 Why are dechallenge and rechallenge generally not useful standard criteria for evaluating congenital malformations caused by prenatal exposure?

Congenital malformations are not serious enough to support causality assessment The developmental outcome may be established before a conventional clinical dechallenge is possible, and rechallenge would be unethical Dechallenge and rechallenge apply only to spontaneous reports from consumers Prenatal exposure cannot be documented retrospectively

Question 7 of 10 Which regulatory lesson is most closely associated with the U.S. handling of thalidomide?

Approval should proceed when a sponsor states that available safety data are adequate Independent scientific review and authority to delay approval are essential when evidence is insufficient Investigational distribution is equivalent to unrestricted marketing approval Effectiveness evidence is unnecessary when a medicine has an established sedative effect

Question 8 of 10 Which factor would make a rare congenital-malformation signal especially detectable without a very large dataset?

A common and poorly defined phenotype with only a modest relative increase A distinctive phenotype associated with a very large relative increase and sufficiently common exposure A high background rate and uncertain exposure information A large number of unrelated adverse-event terms grouped together

Question 9 of 10 Why is reconstruction of the mother's exposure timing particularly important when evaluating suspected teratogenicity?

Congenital abnormalities can only occur after treatment has continued for a minimum duration Different embryonic structures are susceptible during different developmental stages Timing determines whether a case can be entered into a safety database Exposure timing replaces the need to consider alternative causes

Question 10 of 10 How should confounding be addressed when evaluating the thalidomide association?

It should be ignored because the outcome was serious It should be considered, but its explanatory credibility must be assessed against the specificity, magnitude and reproducibility of the phenotype It automatically invalidates all observational evidence It can be excluded solely because exposure was reported by clinicians

QPPV.com

Knowledge Assessment: Thalidomide and Congenital Malformations

Cookie Settings